Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles

Nancy L. Davis, Ian J. Caley, Kevin W. Brown, Michael R. Betts, David M. Irlbeck, Kathryn M. McGrath, Mary J. Connell, David C. Montefiori, Jeffrey A Frelinger, Ronald Swanstrom, Philip R. Johnson, Robert E. Johnston

Research output: Contribution to journalArticle

177 Citations (Scopus)

Abstract

Vaccine vectors derived from Venezuelan equine encephalitis virus (VEE) that expressed simian immunodeficiency virus (SIV) immunogens were tested in rhesus macaques as part of the effort to design a safe and effective vaccine for human immunodeficiency virus. Immunization with VEE replicon particles induced both humoral and cellular immune responses. Four of four vaccinated animals were protected against disease for at least 16 months following intravenous challenge with a pathogenic SIV swarm, while two of four controls required euthanasia at 10 and 11 weeks. Vaccination reduced the mean peak vital load 100-fold. The plasma viral load was reduced to below the limit of detection (1,500 genome copies/ml) in one vaccinated animal between 6 and 16 weeks postchallenge and in another from week 6 through the last sampling time (40 weeks postchallenge). The extent of reduction in challenge virus replication was directly correlated with the strength of the immune response induced by the vectors, which suggests that vaccination was effective.

Original languageEnglish (US)
Pages (from-to)371-378
Number of pages8
JournalJournal of Virology
Volume74
Issue number1
StatePublished - 2000
Externally publishedYes

Fingerprint

Venezuelan Equine Encephalitis Viruses
Venezuelan equine encephalitis virus
Simian immunodeficiency virus
replicon
Simian Immunodeficiency Virus
Replicon
Macaca
Virion
Vaccination
Vaccines
vaccination
vector vaccines
Euthanasia
Human immunodeficiency virus
swarms
euthanasia
Humoral Immunity
Virus Replication
virus replication
viral load

ASJC Scopus subject areas

  • Immunology

Cite this

Davis, N. L., Caley, I. J., Brown, K. W., Betts, M. R., Irlbeck, D. M., McGrath, K. M., ... Johnston, R. E. (2000). Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. Journal of Virology, 74(1), 371-378.

Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. / Davis, Nancy L.; Caley, Ian J.; Brown, Kevin W.; Betts, Michael R.; Irlbeck, David M.; McGrath, Kathryn M.; Connell, Mary J.; Montefiori, David C.; Frelinger, Jeffrey A; Swanstrom, Ronald; Johnson, Philip R.; Johnston, Robert E.

In: Journal of Virology, Vol. 74, No. 1, 2000, p. 371-378.

Research output: Contribution to journalArticle

Davis, NL, Caley, IJ, Brown, KW, Betts, MR, Irlbeck, DM, McGrath, KM, Connell, MJ, Montefiori, DC, Frelinger, JA, Swanstrom, R, Johnson, PR & Johnston, RE 2000, 'Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles', Journal of Virology, vol. 74, no. 1, pp. 371-378.
Davis, Nancy L. ; Caley, Ian J. ; Brown, Kevin W. ; Betts, Michael R. ; Irlbeck, David M. ; McGrath, Kathryn M. ; Connell, Mary J. ; Montefiori, David C. ; Frelinger, Jeffrey A ; Swanstrom, Ronald ; Johnson, Philip R. ; Johnston, Robert E. / Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles. In: Journal of Virology. 2000 ; Vol. 74, No. 1. pp. 371-378.
@article{12a75f9ab1944bd18f5b9dd986db20da,
title = "Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles",
abstract = "Vaccine vectors derived from Venezuelan equine encephalitis virus (VEE) that expressed simian immunodeficiency virus (SIV) immunogens were tested in rhesus macaques as part of the effort to design a safe and effective vaccine for human immunodeficiency virus. Immunization with VEE replicon particles induced both humoral and cellular immune responses. Four of four vaccinated animals were protected against disease for at least 16 months following intravenous challenge with a pathogenic SIV swarm, while two of four controls required euthanasia at 10 and 11 weeks. Vaccination reduced the mean peak vital load 100-fold. The plasma viral load was reduced to below the limit of detection (1,500 genome copies/ml) in one vaccinated animal between 6 and 16 weeks postchallenge and in another from week 6 through the last sampling time (40 weeks postchallenge). The extent of reduction in challenge virus replication was directly correlated with the strength of the immune response induced by the vectors, which suggests that vaccination was effective.",
author = "Davis, {Nancy L.} and Caley, {Ian J.} and Brown, {Kevin W.} and Betts, {Michael R.} and Irlbeck, {David M.} and McGrath, {Kathryn M.} and Connell, {Mary J.} and Montefiori, {David C.} and Frelinger, {Jeffrey A} and Ronald Swanstrom and Johnson, {Philip R.} and Johnston, {Robert E.}",
year = "2000",
language = "English (US)",
volume = "74",
pages = "371--378",
journal = "Journal of Virology",
issn = "0022-538X",
publisher = "American Society for Microbiology",
number = "1",

}

TY - JOUR

T1 - Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles

AU - Davis, Nancy L.

AU - Caley, Ian J.

AU - Brown, Kevin W.

AU - Betts, Michael R.

AU - Irlbeck, David M.

AU - McGrath, Kathryn M.

AU - Connell, Mary J.

AU - Montefiori, David C.

AU - Frelinger, Jeffrey A

AU - Swanstrom, Ronald

AU - Johnson, Philip R.

AU - Johnston, Robert E.

PY - 2000

Y1 - 2000

N2 - Vaccine vectors derived from Venezuelan equine encephalitis virus (VEE) that expressed simian immunodeficiency virus (SIV) immunogens were tested in rhesus macaques as part of the effort to design a safe and effective vaccine for human immunodeficiency virus. Immunization with VEE replicon particles induced both humoral and cellular immune responses. Four of four vaccinated animals were protected against disease for at least 16 months following intravenous challenge with a pathogenic SIV swarm, while two of four controls required euthanasia at 10 and 11 weeks. Vaccination reduced the mean peak vital load 100-fold. The plasma viral load was reduced to below the limit of detection (1,500 genome copies/ml) in one vaccinated animal between 6 and 16 weeks postchallenge and in another from week 6 through the last sampling time (40 weeks postchallenge). The extent of reduction in challenge virus replication was directly correlated with the strength of the immune response induced by the vectors, which suggests that vaccination was effective.

AB - Vaccine vectors derived from Venezuelan equine encephalitis virus (VEE) that expressed simian immunodeficiency virus (SIV) immunogens were tested in rhesus macaques as part of the effort to design a safe and effective vaccine for human immunodeficiency virus. Immunization with VEE replicon particles induced both humoral and cellular immune responses. Four of four vaccinated animals were protected against disease for at least 16 months following intravenous challenge with a pathogenic SIV swarm, while two of four controls required euthanasia at 10 and 11 weeks. Vaccination reduced the mean peak vital load 100-fold. The plasma viral load was reduced to below the limit of detection (1,500 genome copies/ml) in one vaccinated animal between 6 and 16 weeks postchallenge and in another from week 6 through the last sampling time (40 weeks postchallenge). The extent of reduction in challenge virus replication was directly correlated with the strength of the immune response induced by the vectors, which suggests that vaccination was effective.

UR - http://www.scopus.com/inward/record.url?scp=0033988633&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033988633&partnerID=8YFLogxK

M3 - Article

VL - 74

SP - 371

EP - 378

JO - Journal of Virology

JF - Journal of Virology

SN - 0022-538X

IS - 1

ER -